Embryonic stem cell-derived cardiac myocytes are not ready for human trials

Mark E. Anderson, Joshua Goldhaber, Steven R. Houser, Michel Puceat, Mark A. Sussman

Research output: Contribution to journalReview articlepeer-review

37 Scopus citations


Recently, a preclinical report assessed the efficacy, safety, and feasibility of using human embryonic stem cells to regenerate infarcted myocardium in a nonhuman primate model. This commentary evaluates that study by pointing out key weaknesses, offering an alternative perspective, and summarizing major unresolved issues. Our conclusion is that significant challenges remain before human embryonic stem cells are ready for use in clinical trials.

Original languageEnglish (US)
Pages (from-to)335-338
Number of pages4
JournalCirculation research
Issue number3
StatePublished - Jul 18 2014
Externally publishedYes

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Embryonic stem cell-derived cardiac myocytes are not ready for human trials'. Together they form a unique fingerprint.

Cite this